Article
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Jun 2011
Pfaller M A, Diekema D J, Andes D, Arendrup M C, Brown S D, Lockhart S R, Motyl M, Perlin D S
Abstract excerpt
The CLSI established clinical breakpoints (CBPs) for caspofungin (CSF), micafungin (MCF) and anidulafungin (ANF) versus Candida. The same CBP (susceptible (S): MIC ≤ 2 mcg/ml; non-S: MIC > 2 mcg/ml) was applied to all echinocandins and species. More data now allow reassessment of these CBPs. We examined cases of echinocandin failure where both MICs and fks mutations were assessed; wild type (WT) MICs and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.